MedTrace Logo

Polidocanol Versus Glucose Treatment of Telangiectasia Trial

NCT02657252 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 115

Last updated 2018-01-04

Study results available
· View outcomes & findings →

Summary

It will be done a randomized triple-blind study comparing 0,2% polidocanol versus 75% hypertonic glucose of sclerotherapy in lower limbs´ telangiectasis. It will be included only adult women with reticular veins on the side of the thighs and mild venous insufficiency (CEAP 1). The primary endpoint will be efficacy, and secondary will be safety.

Conditions

  • Varicose Veins
  • Telangiectasis

Interventions

DRUG

Glucose

Sclerotherapy of telangiectasis in one lower limb.

DRUG

Polidocanol with Glucose

Sclerotherapy of telangiectasis in one lower limb.

Sponsors & Collaborators

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

    collaborator OTHER_GOV

  • UPECLIN HC FM Botucatu Unesp

    lead OTHER

Principal Investigators

  • Matheus Bertanha, Dr · Botucatu School of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-09-30
Completion
2016-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02657252 on ClinicalTrials.gov